| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Departments of * Pharmacology and
Radiology, New York Medical College, Valhalla,
New York.
| Correspondence to: Dr C. Andrew Powers, Department of Pharmacology, New York Medical College, Valhalla, NY 10595 (e-mail: andrew_powers{at}nymc.edu). |
| Received for publication September 16, 2003; accepted for publication February 10, 2004. |
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
Key words: Testis, androgens, estrogens, aromatase, osteoporosis, prostate, seminal vesicle
In postmenopausal women, hormone replacement regimens that include estrogens are widely used to treat common menopausal complaints and have proven effective in the prevention or treatment of osteoporosis. Similarly, in hypogonadal men, therapy with aromatizable androgens would be expected to relieve problems due to both androgen deficiency and estrogen deficiency. Indeed, T replacement has beneficial effects on bone metabolism in orchidectomized rats (Wakley et al, 1991; Vanderschueren et al, 1992, 2000), and studies of hypogonadal men describe similar actions (Anderson et al, 1997; Behre et al, 1997). Nonetheless, androgen use can be worrisome in men with prostate health concerns and is inadvisable in men with a history of prostate cancer or urethral obstruction due to benign prostatic hypertrophy (Bhasin and Tenover, 1997; Advisory Panel on Testosterone Replacement in Men, 2001; Vermeulen, 2001).
Given the concerns about androgen effects on prostate health in older hypogonadal men, it may often prove more practical to manage problems related to estrogen deficiency, such as osteoporosis. However, agents available for such use can be problematic. Modest estrogen doses have beneficial effects on bone in men (Orwoll, 1998; Lombardi et al, 2001), but T deficiency greatly enhances the estrogen sensitivity of breast tissue (Glass, 1994), and the resulting gynecomastia is intolerable for most men. In contrast, oral bisphosphonates (alendronate and risedronate) prevent osteoporosis by nonhormonal actions specifically targeting bone and have been well tolerated in clinical trials. In general medical practice, however, oral bisphosphonates can be troublesome in patients at risk for upper gastrointestinal problems, and patient compliance with therapy has been disappointing (Ettinger et al, 1998; Kherani et al, 2002; Tosteson et al, 2003). Other agents available for osteoporosis prevention in men either require parenteral injections (parathyroid hormone 1-34) or have less efficacy (intranasal sprays of salmon calcitonin). Thus, an effective alternative to estrogens and oral bisphosphonates may be helpful for many men.
Selective ER modulators (SERMs) such as tamoxifen evoke a novel mix of estrogenic and anti-estrogenic actions that might be advantageous for some hypogonadal men. Tamoxifen acts as an estrogen antagonist in its effects on the breast, rat prolactin (PRL), and certain other targets, yet it also acts as an estrogen agonist to lower blood cholesterol and prevent bone loss in estrogen-deficient female animals and women (Sato et al, 1996; Ke et al, 1997; MacGregor and Jordan, 1998). Indeed, the potential utility of the effects of tamoxifen in males was notable in a recent study of estradiol (E2) and tamoxifen interplay with triiodothyronine (T3) in hypothyroid male rats (Fitts et al, 2001). ORX effects to decrease bone mass and serum growth hormone (GH) were inhibited by tamoxifen—which also lowered serum cholesterol. Moreover, tamoxifen had negligible estrogenic effects on pituitary PRL and did not influence male sex organ growth.
The present study used euthyroid male rats as a preclinical model to further assess the possible value of tamoxifen for men and tested the hypothesis that tamoxifen can protect bone mass and lower cholesterol in males without inducing either sex organ growth (a classic androgen response) or pituitary PRL (a classic estrogen response in the rat). Moreover, tamoxifen (a classic SERM) was directly compared to testosterone propionate (TP, a classic aromatizable androgen) with respect to its efficacy in preventing diverse ORX effects. In addition, the experimental data were subjected to correlation/regression analyses to assess a secondary hypothesis that changes in proximal tibia BMD during gonadal manipulations are partly related to changes in serum GH and insulin-like growth factor I (IGF-I).
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
ORX was performed under halothane-O2 anesthesia 4 days after arrival, and study treatments were started 4 days after surgery (87–92 days of age; mean starting weight = 335 g). Eight rats received only sham surgery to provide testis-intact controls (mean starting weight = 352 g). In young adult rats of the ages studied, gonadectomy and sex hormone therapy produces changes in cancellous bone mass that are clearly evident in 2 weeks and unequivocal in 4 weeks (Wronski et al, 1989; Kalu, 1991; Wakley et al, 1991; Thompson et al, 1995). Thus, a 6-week treatment period was used in this study. Note that similar preclinical models that use aged rats (older than 1 year) employ much longer treatment periods, since it takes much longer for aged rats to exhibit changes in bone mass in response to sex hormone manipulations (see "Discussion").
Experimental Design and Drug Treatments
Six groups of orchidectomized rats received the following drug and hormone
treatments: 1) vehicle solution alone (n = 8); 2) testosterone
17ß-propionate (TP; Sigma Chemical Co, St Louis, Mo) at 1 mg/kg via
subcutaneous (SC) injection 3 times weekly (n = 7); 3) TP at 10 mg/kg via SC
injection 3 times weekly (n = 7); 4) tamoxifen (trans isomer, free base;
Sigma) at 1.0 mg/kg via SC injection once daily (n = 7); 5) TP at 1 mg/kg plus
tamoxifen (n = 7); and 6) TP at 10 mg/kg plus tamoxifen (n = 8). The 8
testis-intact rats received daily injections of vehicle solution. TP and
tamoxifen were initially dissolved in benzyl alcohol (a pharmaceutical solvent
with bacteriostatic and local anesthetic activity) and then diluted with
sesame oil to achieve the desired concentrations in 2% benzyl alcohol: 98%
sesame oil (vol/vol). Injection volumes were 50 µL per 100 g of body
weight.
The above dosing regimens were tailored to fit drug pharmacokinetics. Tamoxifen is a lipophilic agent with a large volume of distribution (>50 L/kg) and an 8-hour plasma half-life in the rat (Borgna and Rochefort, 1981; Robinson et al, 1991). Tamoxifen and its potent metabolite (4-hydroxytamoxifen) have 20- and 48-hour half-lives, respectively, in uterine nuclei (Borgna and Rochefort, 1981), and tamoxifen at 0.7 mg/kg increases nuclear retention of the ER for more than 2 days (Bowman et al, 1982). These pharmacokinetics indicate that once-daily dosing should produce a "steady state" in tamoxifen and 4-hydroxytamoxifen levels in plasma and target tissue nuclei within 4–8 days. A daily tamoxifen dose of 1 mg/kg was used, since it yielded maximal estrogen agonist and antagonist effects in previous dose-response studies (Powers et al, 1989; DiPippo et al, 1995).
T replacement was provided with TP, the first 17-OH ester of T to become widely available for experimental and clinical use and the prototype for such therapeutics (Miescher et al, 1936; Meikle, 1999). TP is more lipophilic than T and is absorbed from oil vehicles much more slowly than T after injection. Once absorbed, TP is rapidly hydrolyzed to T (Fujioka et al, 1986)— which mediates the androgenic effects of TP. The differing disposition of TP dramatically increases its androgenic potency and duration of action compared to T. TP has a large volume of distribution (>70 L/kg) and yields peak levels of plasma T about 24 hours after injection; T levels then decline with roughly a 24-hour half-life (Gerrity, 1979; Fujioka et al, 1986). The pharmacokinetics of TP indicate that 3 SC injections per week will produce a steady state in plasma T in about 6–8 days. TP doses of 1 and 10 mg/kg were used in this study, and androgenic efficacy was assessed relative to maintenance of sex organ weights at levels seen in normal testis-intact males.
During the treatment phase of the study, body weight was measured 3 times per week, and food intake was measured once per week. Rats were housed in gangs of 3–4 rats per cage; thus, total food intake per group was measured during a 24-hour period, and average intake per rat was interpolated. Body temperature was measured weekly with a digital thermometer equipped with a rectal thermocouple probe. This regimen provided an index of treatment effects on thermoregulation.
Tissue Processing
After 6 weeks of treatment, rats were euthanized in random order with
sodium pentobarbital at 100 mg/kg (intraperitoneally) between 10:30
AM and 3:30 PM. Blood, anterior pituitaries, and right
tibias were collected within 5 minutes of pentobarbital injection as
previously described (DiPippo et al,
1995; Fitts et al,
1998). Blood samples were allowed to clot for 5 minutes at room
temperature, cooled on ice, and then refrigerated at 5°C; serum was
collected the next day, aliquoted, and stored at -80°C until assay. The
right tibia was stripped of most muscle and connective tissue and stored in
70% ethanol for subsequent measurements of tibia length (an index of
longitudinal growth) and bone mineral density (BMD). Anterior pituitaries were
sonicated in 400 µL of homogenization buffer (10 mmol of sodium phosphate
per liter, 150 mmol of NaCl per liter, and 0.1% Triton X-100, pH 7.5),
separated into aliquots, and stored at -20°C until assay.
Seminal vesicles and ventral prostate lobes were dissected, drained of their luminal contents, and weighed. The weights of these male sex accessory organs provided a reliable index of circulating bioavailable androgenic activity. Unlike radioimmunoassays (RIAs) for total T, measures of androgen bioactivity are sensitive to differences in free T arising from changes in sex hormone–binding globulin or differences in dihydrotestosterone formation in target tissues.
Analysis of BMD
Tibia BMD was measured by dual-energy x-ray absorptiometry with a Hologic
QDR1000 (Waltham, Mass) as previously described
(DiPippo et al, 1995; Fitts et al, 1998). Image
analysis software (Hologic) calculated bone mineral content (in grams),
cross-sectional area (square centimeters), and BMD (grams per square
centimeter) in 2 regions: the proximal tibia and the tibia diaphysis. The
proximal tibia (upper one third of tibia length) is relatively enriched in
cancellous bone and has a higher ratio of cancellous to cortical bone than the
diaphysis (middle one third of tibia length)
(Kalu, 1991;
Shen et al, 1993).
Cholesterol and Glucose Analyses
Total cholesterol was measured using a colorimetric kit (Sigma). Serum
glucose was measured as an index of carbohydrate metabolism using a
colorimetric kit (Stanbio Laboratories, San Antonio, Tex).
Assay of Serum GH and IGF-I
Serum GH and IGF-I levels were used to assess changes in the GH–IGF-I
axis. Total serum levels of IGF-I were determined using an RIA kit (Nichols
Diagnostics, San Juan Capistrano, Calif) after extraction of IGF-I from serum.
IGF-I in rat serum was separated from IGF-binding proteins (IGFBPs) using the
acid-ethanol extraction method described by Crawford et al
(1992). Serum samples (100
µL) were mixed with 900 µL of acid-ethanol solution (12.5% 2 M HCl:87.5%
ethanol [vol/vol]), incubated for 30 minutes at room temperature, and then
centrifuged at 1500 x g for 30 minutes at 5°C
(protein/IGFBP precipitation 1). A 200-µL sample of the supernate was then
mixed with 100 µL 0.855 M Tris base (pH 11), incubated 30 minutes at room
temperature, and centrifuged at 1500 x g for 30 minutes at
5°C (protein/IGFBP precipitation 2). A 100-µL sample of the final
supernate was mixed with 1.4 mL of phosphate buffer (pH 7.5) and used for RIA.
This acid-ethanol extraction method has previously been validated for RIA of
total IGF-I in male and female rat serum by comparison with results using
high-pressure liquid chromatography (HPLC) methodology
(Crawford et al, 1992). The
sensitivity of the IGF-I RIA was 57.5 ng/mL with the serum extraction protocol
used, and the assay precision (the intra-assay coefficient of variation) was
2.13%.
Serum GH was determined using a rat GH RIA kit (Amersham Pharmacia Biotech, Piscataway, NJ). The sensitivity of the GH RIA was 3.2 ng/mL (with 50-µL serum aliquots per RIA tube), and the intra-assay coefficient of variation was 1.97%.
Anterior Pituitary Analyses
PRL and glandular kallikrein are estrogen-induced proteins in the anterior
pituitary with differing sensitivities to E2
(Hatala and Powers, 1988a; Powers et al, 1989); their
measurement provided a sensitive index of estrogenic bioactivity. PRL levels
were determined using a rat PRL RIA kit (Amersham). The sensitivity of the PRL
RIA was 2.0 µg per pituitary with the sample dilution used, and the
intra-assay coefficient of variation was 1.45%.
Levels of glandular kallikrein were measured enzymatically using D-Val-Leu-Arg-p-nitroanilide as previously described (Hatala and Powers, 1988a). Total pituitary protein provided an index of estrogenic effects to induce anterior pituitary hyperplasia (Hatala and Powers, 1988a).
Statistical Analysis of Grouped Data
Data were subjected to an analysis of variance and then to a multiple
comparisons analysis with the Fisher least significant difference test;
P < .05 was the criterion of significance. Serum GH values in all
statistical tests were log transformed to normalize variances. Data in the 1
mg/kg TP group were also transformed to express the percentage of prevention
of the various ORX effects [% prevention = 100 x (observed value -
orchidectomized group mean)/(intact group mean - orchidectomized group mean)].
This format enabled a formal statistical comparison of the responsiveness of
different parameters to TP at 1 mg/kg.
Correlation/Regression Analysis
Linear regression analysis and the Pearson correlation coefficient
(r) were used to identify significant associations between GH or
IGF-I and other parameters. These analyses were performed on individual rat
data sets (single units of association) from 41 of the 44 orchidectomized rats
in the study. Serum GH and IGF-I data were not obtained for 3 rats that did
not yield enough serum for RIAs (1 in the tamoxifen group; 2 in the 10 mg/kg
TP + tamoxifen group).
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
Effects on Serum Cholesterol
Serum cholesterol was increased in orchidectomized rats relative to
testis-intact controls (Figure
2). TP treatment blocked this increase, with doses of 1 and 10
mg/kg yielding equivalent effects. Tamoxifen also decreased cholesterol in
orchidectomized rats, but unlike TP, tamoxifen yielded levels significantly
lower than in intact controls. TP had little effect on serum cholesterol in
orchidectomized rats receiving tamoxifen
(Figure 2).
|
Effects on Prostate and Seminal Vesicle Weight
Growth of male sex accessory organs is androgen-dependent, and seminal
vesicle and ventral prostate wet weights provided an index of endogenous
androgenic bioactivity. Orchidectomized rats displayed a marked atrophy of the
seminal vesicle and prostate relative to testis-intact rats
(Figure 3), and treatment with
TP at 1 mg/kg maintained sex organ weights at intact control levels. Sex organ
weights in rats given TP at 10 mg/kg were almost twice that of intact
controls, indicating supraphysiologic stimulation. Tamoxifen had no effect on
sex organ weight and neither inhibited nor enhanced TP actions.
|
Effects on Somatic Growth
Compared to testis-intact rats, orchidectomized rats gained 30% less body
weight, and this was coupled with a retardation of longitudinal growth (ie, a
1.1-mm decrease in tibia length) (Table
1). Androgen replacement with TP at 1 mg/kg prevented 84% and 64%
of ORX effects on weight gain and tibia length, respectively, but TP at 10
mg/kg did not—probably because of dose-related estrogenic activity (see
below).
|
Tamoxifen totally inhibited body weight gain and decreased tibia length a further 1.4 mm relative to orchidectomized controls. TP modestly increased weight gain and tibia length in rats given tamoxifen but did not reverse the bulk of tamoxifen effects (Table 1).
Effects on Serum GH and Serum IGF-I
ORX markedly decreased serum GH relative to testis-intact rats
(Table 1); TP at 1 mg/kg had no
effect on GH, but TP at 10 mg/kg prevented about 70% of the decrease.
Tamoxifen also partly restored serum GH in orchidectomized rats and interacted
with TP to yield GH levels matching those in testis-intact rats. Indeed, TP
alone at 1 mg/kg lacked effect on GH but enhanced tamoxifen effects to
increase GH (Table 1).
Orchidectomized rats also had lower serum IGF-I levels than testis-intact rats (-130 ng/mL) (Table 1). TP doses of 1 mg/kg prevented this effect of ORX. However, TP doses of 10 mg/kg had the opposite effect and lowered IGF-I a further 87 ng/mL, an action consistent with the emergence of estrogenic activity at high doses. Tamoxifen caused even larger decreases in serum IGF-I (-167 ng/mL), and TP had little effect on IGF-I in rats given tamoxifen.
Effects on Food Intake, Serum Glucose, and Body Temperature
There were no significant group differences in food consumption per
kilogram of body weight (data not shown). Serum glucose was unaffected by ORX
or TP treatment, whereas tamoxifen caused small decreases
(Table 1). Body temperature was
0.9° higher in orchidectomized rats than in testis-intact rats, and TP
prevented this increase (Table
1); body temperature was unaffected by tamoxifen. These data match
prior results from this laboratory and indicate that changes in food intake,
glucose metabolism, or thermogenesis are unlikely to explain changes in BMD,
cholesterol, or growth.
Effects on Anterior Pituitary Levels of PRL, Glandular Kallikrein, and Total Protein
Anterior pituitary PRL and glandular kallikrein levels are higher in female
than in male rats due to induction by ovarian estrogens, and tamoxifen acts as
an antagonist in these estrogen responses (Hatala and Powers,
1987,
1988b;
Powers et al, 1989). These
measures provided indices of endogenous estrogenic bioactivity. ORX did not
alter PRL levels (Table 2). PRL
also was unaffected by TP or tamoxifen at 1 mg/kg, but TP at 10 mg/kg induced
an increase that was blocked by tamoxifen.
|
Unlike PRL, glandular kallikrein activity in the anterior pituitary (total or per milligram of protein) increased with ORX, and TP at 1 mg/kg prevented the increase (Table 2). Tamoxifen also reduced total pituitary kallikrein, but its effects were additive with TP. Moreover, unlike TP, tamoxifen did not lower kallikrein activity per milligram of protein. Thus, the tamoxifen effect on total kallikrein was secondary to a nonspecific decrease in total pituitary protein (Table 2). Neither ORX nor TP notably altered total pituitary protein or tamoxifen effects on this parameter.
Overall, the PRL data provided evidence for the presence of a low level of estrogenic bioactivity in orchidectomized rats given TP at 10 mg/kg but not in rats given TP at 1 mg/kg or in testis-intact rats.
Differential Prevention of ORX Effects by TP at 1 mg/kg
Informal comparisons of the TP responsiveness of various parameters
indicated that BMD and serum GH were much less responsive to TP at 1 mg/kg
than other parameters. To statistically confirm this observation, data for
each parameter in the TP group given 1 mg/kg were transformed to express the
percentage of prevention of the ORX effect (see "Materials and
Methods"). This transformation enabled a formal statistical comparison
of the responsiveness of the different parameters to TP at 1 mg/kg
(Figure 4). The greatest
responsiveness to TP at 1 mg/kg was displayed by cholesterol (109% prevention)
and seminal vesicle weight (98.2% prevention). BMD (31% prevention) and serum
GH (-8.5% prevention) had the lowest responsiveness and were the only
parameters whose responsiveness to TP at 1 mg/kg significantly differed from
the seminal vesicles.
|
Correlation/Regression Analyses
Sex hormone effects on longitudinal growth in the rat are mediated by
alterations in the GH–IGF-I axis, and similar mechanisms may contribute
to sex hormone effects on bone remodeling and BMD (see
"Discussion"). The relation of serum GH and IGF-I to BMD and
somatic growth was studied using the individual data sets of orchidectomized
rats (n = 41); these data sets capture changes associated with TP and
tamoxifen treatments.
Serum GH and IGF-I levels were inversely related to each other (Table 3). This is a distinctive feature of the GH–IGF-I axis during estrogenic manipulations in the presence of T3 (Fitts et al, 2001). Proximal tibia BMD also exhibited a significant positive correlation with serum GH but displayed a significant negative correlation with serum IGF-I (Table 3; Figure 5). Moreover, GH and IGF-I were more related to BMD than to each other, suggesting that GH and IGF-I were each independently related to BMD. This was supported by multiple linear regression analysis. Regression predictions [BMD x 103 = 300.9 + (12.02 x log GH) - (0.06425 x IGF-I)] were well correlated with observed BMD (r = 0.692, P < .001), and the GH and IGF-I coefficients each made significant contributions to the prediction of BMD (P < .01).
|
|
Serum IGF-I also exhibited strong positive correlations with body weight gain and tibia length, while GH exhibited negative correlations with these measures (Table 3). Significant coefficients for IGF-I (P < .0001) as well as GH (P < .05) were obtained in the multiple regression predicting body weight gain. For the multiple regression predicting tibia length, however, only the IGF-I coefficient was significant (P < .01).
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
The present data resemble findings in male rats castrated at 49 days and treated with pellets containing T for 3 weeks; T pellets that prevented cancellous bone loss also suppressed growth and evoked supraphysiologic sex organ weights (Wakley et al, 1991). However, the opposite was reported in aged rats orchidectomized at 12 months and treated with T-filled Silastic capsules for 15 weeks (Vanderschueren et al, 2000). Cancellous bone loss was fully prevented by T capsules that preserved only 50% of seminal vesicle and prostate weights; thus, bone seemed more sensitive to low T doses than male sex accessory organs renowned for their T sensitivity.
The report of Vanderschueren et al (2000) was notable, since it suggested that low T doses might preserve bone and muscle mass in aging men without jeopardizing prostate health (see Vermeulen, 2001). However, further study of this issue seems warranted. Indeed, the influence of different methods of T dosing merits consideration. Classic pharmacokinetic principles dictate that regular TP injections will rapidly yield a steady state that will maintain plasma T within a fairly narrow range for as long as dosing is continued (Meikle, 1999). Steroid-filled Silastic capsules, however, have much different pharmacokinetics (Kincl and Rudel, 1971; Longer and Robinson, 1985). In vivo steroid release by Silastic capsules rapidly peaks and then undergoes an exponential decay featuring a large and rapid decline in its initial phase, which is followed by a longer phase of slowly declining release. This is well documented with Norplant, the only Silastic capsule system approved for systemic clinical therapy. Norplant releases contraceptive doses of levonorgestrel for more than 5 years, but steroid release and plasma levels peak 24 hours after implantation, decline 60%–80% by 18 months, and then decline 4%–5% per year (Drug Facts and Comparisons, 2001). Correspondingly, the sex organ weights of castrated male rats peak 4–6 weeks after T-capsule implantation and then exhibit progressive and sizable declines (Schenck et al, 1977). Such pharmacokinetics may confound efforts to compare the T sensitivity of tissues that differ in the dynamics of their response to T. In particular, male sex organs respond to T manipulations within days (Parkes, 1936), but 12–16 weeks are required for significant changes in bone mass to evolve in aged rats (Wronski et al, 1989; Kalu, 1991; Vanderschueren et al, 1992). Thus, in aged rats bearing T capsules for 15 weeks, sex organ weights may reflect the T-release rate of the 15th week, but bone mass may still show the influence of the much higher rates of T release 8–12 weeks earlier. This scenario highlights the dosing limitations of steroidfilled Silastic capsules.
In normal male rats and men, the miniscule amounts of estrogen made by the testis and other organs appear inadequate for a role as a circulating endocrine hormone. However, such estrogen production has been postulated to yield localized autocrine and paracrine effects that are physiologically important in males (Sharpe, 1998; Simpson et al, 2000). In the present study, TP at 1 mg/kg provided a physiologic level of T replacement for sex organ growth (an androgenic response), somatic growth (an anabolic response), serum IGF-I, cholesterol, pituitary kallikrein, and body temperature. Nonetheless, TP at 1 mg/kg had little effect on BMD or serum GH, and neither ORX nor TP at 1 mg/kg altered pituitary PRL, a sensitive index of estrogenic activity (Powers et al, 1989; DiPippo et al, 1995). Such results are difficult to reconcile with the hypothesis that physiologic levels of T and nongonadal aromatase yield sufficient levels of localized estrogenic activity to explain testis effects on bone mass and serum GH. Nonetheless, the data are consistent with the core concept that a substance other than T mediates testis effects on such targets.
The effects of TP at 10 mg/kg on sex organ growth, cholesterol, body temperature, and pituitary kallikrein were consistent with a modest progression of the androgenic effects evoked by TP at 1 mg/kg. However, the actions of TP at 10 mg/kg on BMD, somatic growth, GH, IGF-I, and PRL were distinct and were consistent with the emergence of effects produced by an estrogen such as E2. Indeed, tamoxifen antagonizes PRL induction by E2 (Powers et al, 1989; MacGregor and Jordan, 1998), and the tamoxifen blockade of PRL increases evoked by TP at 10 mg/kg linked ERs to this response. Nonetheless, it should be emphasized that ORX did not affect pituitary PRL, a sensitive E2 target in the rat. Moreover, TP at 10 mg/kg just barely restored BMD and only partially restored serum GH but yielded PRL levels well above those of normal male rats, failed to reverse ORX effects on somatic growth, and further decreased serum IGF-I. Such data seem incongruous with the idea that nongonadal production of an E2-like estrogen from T can explain testis effects on BMD and serum GH. Rather, the data seem to suggest that a substance other than T or its estrogenic metabolites is involved in such testis effects.
The GH–IGF-I axis powerfully stimulates longitudinal bone growth, which involves a cyclic interplay of chondrocyte growth, endochondral ossification, and bone modeling coordinated by multiple hormone and cytokine signaling systems (Ohlsson et al, 1993; Williams et al, 1998; Spelsberg et al, 1999). The GH–IGF-I axis is also required for the maintenance of bone mass in adults (Holmes and Shalet, 1996; Ohlsson et al, 1998). In rats and men, adult-onset GH deficiency accelerates bone loss, and GH stimulates bone remodeling in a way that enhances bone formation more than bone resorption to eventually yield gains in BMD (Holmes and Shalet, 1996; Ohlsson et al, 1998). The role of IGF-I in such GH effects, however, is not fully understood.
Sex hormone actions on the GH–IGF-I axis are largely responsible for sexual dimorphisms in longitudinal bone growth (Jansson et al, 1985; Ohlsson et al, 1993; Gatford et al, 1998), and related mechanisms may contribute to sex hormone effects on bone mass (Holmes and Shalet, 1996; Ohlsson et al, 1998). Indeed, the disparate responses of the GH–IGF-I axis to different TP doses and tamoxifen were suggestive of a link to BMD. Thus, BMD increases evoked by tamoxifen were attended by GH increases and IGF-I decreases, while TP at 1 mg/kg failed to raise GH or lower IGF-I and lacked effect on BMD, and TP at 10 mg/kg produced a BMD increase that was again coupled with GH increases and IGF-I decreases. Moreover, the enhancement of tamoxifen effects on BMD by TP at 1 mg/kg was coupled with potentiation of tamoxifen effects to increase GH. The relation of serum GH and IGF-I to BMD was more rigorously evaluated by correlation/regression analyses of the individual rat data sets. The resulting multiple linear regression statistics indicated that about 50% of the variation in proximal tibia BMD in experimental rats is related to variations in serum GH and IGF-I (ie, r2 = 0.479). Equivalent multiple regression results were reported in an analysis of orchidectomized, hypothyroid rats during estrogenic manipulations in the presence of T3 replacement (r2 = 0.504) (Fitts et al, 2001); thus, the present findings match prior results. Although such regressions do not prove causation, they satisfy a key prerequisite of the hypothesis that changes in serum GH and IGF-I contribute to sex hormone and tamoxifen effects on BMD. Direct estrogen effects on bone also contribute to changes in BMD (Spelsberg et al, 1999). Thus, gonadal regulation of BMD seems likely to involve a coordinated interplay of direct sex hormone effects on bone and indirect actions secondary to modulation of the GH–IGF-I axis.
Many GH effects reflect its action to elevate serum IGF-I (the somatomedin hypothesis) (Le Roith et al, 2001), and regression analyses examining T3 effects in hypothyroid, orchidectomized rats exemplify core predictions of this hypothesis (Fitts et al, 2001). In particular, serum GH and IGF-I exhibited a direct relationship to each other as well as measures of somatic growth, and serum IGF-I more closely predicted somatic growth than GH. It was also notable that BMD showed little relation to GH or IGF-I levels during T3 manipulations, despite large changes in GH and IGF-I (Fitts et al, 2001). A strong direct relationship between serum IGF-I and measures of somatic growth was also present during the sex hormone and tamoxifen manipulations of this study and prior work (Fitts et al, 2001). However, a novel pattern of associations among GH, IGF-I, and BMD emerged when sex hormone and tamoxifen manipulations were performed: serum GH and IGF-I became inversely related (a reversal of the relationship seen during T3 manipulations), and BMD increased as GH levels rose and IGF-I levels fell. Such findings appear incompatible with classic predictions of the somatomedin hypothesis but suit the core concept of the dual-effector hypothesis of GH actions (Green et al, 1985). A similar conclusion was reached in a recent study of the skeletal structure of IGF-I–deficient mice (Bikle et al, 2001). Thus, effector mechanisms distinct from those affecting somatic growth may mediate BMD responses to GH in the presence of sex hormones. On the whole, the above findings suggest that gonadal hormones can transform the regulation of the GH–IGF-I axis and create a distinct physiologic state in which serum GH increases are coupled with decreases in serum IGF-I. The altered balance of systemic GH to IGF-I signaling seems likely to modulate bone growth and remodeling and might also be relevant to gonadal effects on other physiologic systems.
The positive correlation between serum GH and BMD is consistent with the role of GH in maintaining bone mass (Ohlsson et al, 1998). However, the inverse relation between IGF-I and BMD may seem paradoxical, since IGF-I is essential for bone growth, and some studies of osteoporotic patients have reported positive correlations between IGF-I and cancellous BMD (Kurland et al, 1997; Langlois et al, 1998; Garnero et al, 2000). Also, a complex gene locus that lowers serum IGF-I and BMD in mice has been reported (Bouxsein et al, 2002). Nonetheless, exogenous IGF-1 has shown little promise in osteoporotic patients, and corresponding rat studies have reported increases (Ammann et al, 1993; Bagi et al, 1994), no effect (Narusawa et al, 1995), and decreases in cancellous bone mass (Ibbotson et al, 1992; Tobias et al, 1992). On the other hand, cancellous bone mass is increased in IGF-I–deficient mice (Bikle et al, 2001), which fits well with the present data. Even more importantly, animal and human studies have consistently shown that estrogen or SERM treatments that reduce bone turnover and prevent bone loss also yield decreases in serum IGF-I (Wiedemann et al, 1976; Clemmons et al, 1980; Kalu et al, 1994; Borski et al, 1996; Goodman-Gruen and Barrett-Conner, 1996; Fitts et al, 1998, 2001). In the rat, this is associated with decreases in hepatic IGF-I synthesis (Murphy and Friesen, 1988; Huynh et al, 1993; Krattenmacher et al, 1994; Borski et al, 1996) and reductions in serum IGFBP-3, a GH-sensitive IGFBP whose regulation sometimes parallels IGF-I (Kalu et al, 1994; Rosen, 1999; Arjmandi et al, 2000). Thus, the inverse relationship between IGF-I and cancellous BMD suitably fits the metabolic and therapeutic actions of estrogens and SERMs.
In conclusion, in this preclinical modeling study using male rats, tamoxifen blocked ORX effects on bone mass and GH without altering sex organ growth. Such features of tamoxifen could be advantageous for osteoporosis prevention in hypogonadal men when androgens or other anti-osteoporosis agents are undesirable. Unexpectedly, a TP dose that prevented ORX-induced sex organ atrophy did not protect bone mass, and supraphysiologic sex organ growth accompanied bone protection achieved with a larger TP dose. Thus, sex organ hyperstimulation might limit the value of androgens for osteoporosis prevention. The results also imply that products other than T or its nongonadal metabolites are involved in testis effects on bone mass and GH in the rat and show that gonadal effects on bone mass are correlated with novel changes in GH–IGF-I axis function.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Ammann P, Rizzoli R, Muller K, Slosman D, Bonjour JP. IGF-I and pamidronate increase bone mineral density in ovariectomized adult rats. Am J Physiol. 1993; 65: E770 -E776.
Anderson FH, Francis RM, Peaston RT, Wastell HJ. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res. 1997;12: 472 -478.[Medline]
Arjmandi BH, Birnbaum RS, Juma S, Barengolts E, Kukreja SC. The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms. Calcif Tissue Int. 2000; 66: 61 -65.[Medline]
Bagi CM, Brommage R, Deleon L, Adams S, Rosen D, Sommer A. Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats. J Bone Miner Res. 1994; 9: 1301 -1312.[Medline]
Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term
effect of testosterone therapy on bone mineral density in hypogonadal men.
J Clin Endocrinol Metab. 1997; 82: 2386
-2390.
Bhasin S, Tenover JS. Age-associated sarcopenia—issues in the
use of testosterone as an anabolic agent in older men. J Clin
Endocrinol Metab. 1997;82: 1659
-1660.
Bikle D, Majumdar S, Laib A, et al. The skeletal structure of insulin-like growth factor I-deficient mice. J Bone Miner Res. 2001;16: 2320 -2329.[Medline]
Borgna JL, Rochefort H. Hydroxylated metabolites of tamoxifen are
formed in vivo and bound to estrogen receptor in target tissues. J
Biol Chem. 1981;256: 859
-868.
Borski RJ, Tsai W, De-Mott-Friberg R, Barkan AL. Regulation of somatic growth and the somatotropic axis by gonadal steroids: primary effect on insulin-like growth factor I expression and secretion. Endocrinology. 1996; 137: 3253 -3259.[Abstract]
Bouxsein ML, Rosen CJ, Turner CH, et al. Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo. J Bone Miner Res. 2002; 17: 570 -579.[Medline]
Bowman SP, Leake A, Morris ID. Hypothalamic, pituitary and uterine cytoplasmic and nuclear oestrogen receptors and their relationship to the serum concentration of tamoxifen and its metabolite, 4-hydroxytamoxifen, in the ovariectomized rat. J Endocrinol. 1982; 94: 167 -175.[Abstract]
Clemmons DR, Underwood LE, Ridgeway EC, Kliman B, Kjellberg RN, Van Wyk JJ. Estradiol treatment of acromegaly: reduction of immunoreactive somatomedin-C and improvement of metabolic status. Am J Med. 1980;69: 571 -575.[Medline]
Crawford BA, Martin JL, Howe CJ, Handelsman DJ, Baxter RC. Comparison of extraction methods for insulin-like growth factor-I in rat serum. J Endocrinol. 1992; 134: 169 -176.[Abstract]
Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000; 163: 181 -186.[Medline]
DiPippo VA, Lindsay R, Powers CA. Estradiol and tamoxifen interactions with thyroid hormone in the ovariectomized-thyroidectomized rat. Endocrinology. 1995; 136: 1020 -1033.[Abstract]
Drug Facts and Comparisons. Levonorgestrel implants. In: Drug Facts and Comparisons 2001: Pocket Version. St Louis, Mo: Facts and Comparisons Publishing; 2001: 103 -105.
Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm. 1998;4: 488 -492.
Faustini-Fustini M, Rochira V, Carani C. Oestrogen deficiency in men: where are we today? Eur J Endocrinol. 1999; 140: 111 -129.[Medline]
Fisher B, Costatino JP, Wickerham DL, and other National Surgical
Adjuvant Breast and Bowel Investigators. Tamoxifen for prevention of breast
cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1
Study. J Natl Cancer Inst. 1998; 90: 1371
-1388.
Fitts JM, Klein RM, Powers CA. Comparison of tamoxifen effects on
the actions of triiodothyronine or growth hormone in the
ovariectomized-hypothyroid rat. J Pharmacol Exp Ther. 1998; 286: 392
-402.
Fitts JM, Klein RM, Powers CA. Estrogen and tamoxifen interplay
with T3 in male rats: pharmacologically distinct classes of estrogen responses
affecting growth, bone, and lipid metabolism, and their relation to serum GH
and IGF-I. Endocrinology. 2001; 142: 4223
-4235.
Fujioka M, Shinohara Y, Baba S, Irie M, Inoue K. Pharmacokinetic properties of testosterone propionate in normal men. J Clin Endocrinol Metab. 1986;63: 1361 -1364.[Abstract]
Garnero P, Sornay-Rendu E, Delmas PD. Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet. 2000;355: 898 -899.[Medline]
Gatford KL, Egan AR, Clarke IJ, Owens PC. Sexual dimorphism of the somatotrophic axis. J Endocrinol. 1998; 157: 373 -389.[Medline]
Gerrity M. The Role of Testosterone in the Testes-Pituitary Feedback Loop and the Relative Ability of Different Forms of Testosterone to Produce Functional Androgenicity in the Castrated Male Rat [dissertation]. Valhalla, NY: New York Medical College; 1979 .
Glass AR. Gynecomastia. Endocrinol Metab Clin North Am. 1994;23: 825 -837.[Medline]
Goodman-Gruen D, Barrett-Conner E. Effect of replacement estrogen on insulin-like growth factor-I in postmenopausal women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1996; 81: 4268 -4271.[Abstract]
Green H, Morikawa M, Nixon T. A dual effector theory of growth-hormone action. Differentiation. 1985; 29: 195 -198.[Medline]
Hatala MA, Powers CA. Dynamics of estrogen induction of glandular kallikrein in the rat anterior pituitary. Biochim Biophys Acta. 1987;926: 258 -263.[Medline]
Hatala MA, Powers CA. Glandular kallikrein in estrogen-induced
pituitary tumors: time course of induction and correlation with prolactin.
Cancer Res. 1988a; 48: 4158
-4162.
Hatala MA, Powers CA. Development of the sex difference in glandular kallikrein and prolactin levels in the anterior pituitary of the rat. Biol Reprod. 1988b; 38: 846 -852.[Abstract]
Holmes SJ, Shalet SM. Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Horm Res. 1996; 45: 86 -93.[Medline]
Huynh HT, Tetenes E, Wallace L, Pollak M. In vivo inhibition of
insulin-like growth factor I gene expression by tamoxifen. Cancer
Res. 1993;53: 1727
-1730.
Ibbotson KJ, Orcutt CM, D'Souza SM, Paddock CL, Arthur JA, Jankowsky ML, Boyce RW. Contrasting effects of parathyroid hormone and insulin-like growth factor I in an aged ovariectomized rat model of postmenopausal osteoporosis. J Bone Miner Res. 1992; 7: 425 -432.[Medline]
Jansson J-O, Eden S, Isaksson O. Sexual dimorphism in the control of growth hormone secretion. Endocr Rev. 1985; 6: 128 -150.[Abstract]
Kalu DN. The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 1991; 15: 175 -192.[Medline]
Kalu DN, Arjmandi BH, Liu CC, Salih MA, Birnbaum RS. Effects of ovariectomy and estrogen on the serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3. Bone Miner. 1994;25: 135 -148.[Medline]
Ke HZ, Chen HK, Simmons HA, et al. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone. 1997; 20: 31 -39.[Medline]
Kherani RB, Papaioannou A, Adachi JD. The long-term tolerability of bisphosphonates in postmenopausal osteoporosis: a comparative review. Drug Saf. 2002;25: 781 -790.[Medline]
Kincl FA, Rudel HW. Sustained release hormonal preparations. Acta Endocrinol Suppl (Copenh). 1971; 151: 3 -30.
Krattenmacher R, Knauthe R, Parczyk K, Walker A, Hilgenfeldt U, Fritzemeier KH. Estrogen action on hepatic synthesis of angiotensinogen and IGF-I: direct and indirect estrogen effects. J Steroid Biochem Mol Biol. 1994;48: 207 -214.[Medline]
Kurland ES, Rosen CJ, Cosman F, et al. Insulin-like growth factor-I
in men with idiopathic osteoporosis. J Clin Endocrinol
Metab. 1997;82: 2799
-2805.
Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW,
Kiel DP. Association between insulin-like growth factor I and bone mineral
density in older women and men: the Framingham Heart Study. J Clin
Endocrinol Metab. 1998;83: 4257
-4262.
Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin
hypothesis: 2001. Endocr Rev. 2001; 22: 53
-74.
Lombardi G, Zarrilli S, Colao A, Paesano L, Di Somma C, Rossi F, De Rosa M. Estrogens and health in males. Mol Cell Endocrinol. 2001;178: 51 -55.[Medline]
Longer MA, Robinson JR. Sustained-release drug delivery systems. In: Gennaro AR, ed. Remington's Pharmaceutical Sciences. Easton, Pa: Mack Publishing Co; 1985: 1644 -1661.
MacGregor JI, Jordan VC. Basic guide to the mechanisms of
antiestrogen action. Pharmacol Rev. 1998; 50: 151
-196.
Meikle AW. Androgen replacement therapy of male hypogonadism. In: Meikle AW, ed. Contemporary Endocrinology: Hormone Replacement Therapy. Totowa, NJ: Humana Press; 1999: 263 -305.
Miescher K, Weinstein A, Tschopp E. The activation of the male sex hormones. II. Biochem J. 1936; 30: 1977 -1990.
Murphy LJ, Friesen HG. Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor I gene expression in the ovariectomized hypophysectomized rat. Endocrinology. 1988; 122: 325 -332.[Abstract]
Narusawa K, Nakamura T, Suzuki K, Matsuoka Y, Lee LJ, Tanaka H, Seino Y. The effects of recombinant human insulin-like growth factor (rhIGF)-1 and rhIGF-1/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy. J Bone Miner Res. 1995;10: 1853 -1864.[Medline]
Oeflein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M. Skeletal fracture associated with androgen suppression-induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001; 166: 1724 -1728.[Medline]
Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC.
Growth hormone and bone. Endocr Rev. 1998; 19: 55
-79.
Ohlsson C, Isgaard J, Tornell J, Nilsson A, Isaksson OG, Lindahl A. Endocrine regulation of longitudinal bone growth. Acta Paediatr. 1993;82(suppl 391): 33 -40.
Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin North Am. 1998;27: 349 -367.[Medline]
Oz OK, Zerwekh JE, Fisher C, Graves K, Nanu L, Millsaps R, Simpson ER. Bone has a sexually dimorphic response to aromatase deficiency. J Bone Miner Res. 2000; 15: 507 -514.[Medline]
Parkes AS. Increasing the effectiveness of testosterone. Lancet. 1936;231: 674 -676.
Powers CA, Hatala MA, Pagano PJ. Differential responses of pituitary kallikrein and prolactin to tamoxifen and chlorotrianisene. Mol Cell Endocrinol. 1989; 66: 93 -100.[Medline]
Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos. 1991; 19: 36 -43.[Abstract]
Rochira V, Balestrieri A, Faustini-Fustini M, Carani C. Role of estrogen on bone in the human male: insights from the natural models of congenital estrogen deficiency. Mol Cell Endocrinol. 2001; 178: 215 -220.[Medline]
Rosen CJ. Serum insulin-like growth factors and insulin-like growth
factor-binding proteins: clinical implications. Clin
Chem. 1999;45: 1384
-1390.
Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996; 10: 905 -912.[Abstract]
Schenck B, Schopflin G, Neumann F. Comparison of the biological effectiveness of injected testosterone propionate and testosterone released from silastic capsules. Arzneim-Forsch. 1977; 27: 1586 -1588.[Medline]
Sharpe RM. The roles of oestrogen in the male. Trends Endocrinol Metab. 1998;9: 371 -377.[Medline]
Shen V, Dempster DW, Birchman R, Xu R, Lindsay R. Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J Clin Invest. 1993;91: 2479 -2487.
Simpson E, Rubin G, Clyne C, Robertson K, O'Donnell L, Jones M, Davis S. The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab. 2000; 11: 184 -188.[Medline]
Spelsberg TC, Subramaniam M, Riggs BL, Khosla S. The actions and
interactions of sex steroids and growth factors/cytokines on the skeleton.
Mol Endocrinol. 1999; 13: 819
-828.
Thompson DD, Simmons HA, Pirie CM, Ke HZ. FDA guidelines and animal models for osteoporosis. Bone. 1995; 17(suppl): 125S -133S.[Medline]
Tobias JH, Chow JW, Chambers TJ. Opposite effects of insulin-like growth factor-I on the formation of trabecular and cortical bone in adult female rats. Endocrinology. 1992; 131: 2387 -2392.[Abstract]
Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B. Early discontinuation of treatment for osteoporosis. Am J Med. 2003; 115: 209 -216.[Medline]
Vanderschueren D, Van Herck E, de Coster R, Bouillon R. Aromatization of androgens is important for skeletal maintenance of aged male rats. Calcif Tissue Int. 1996; 59: 179 -183.[Medline]
Vanderschueren D, Van Herck E, Nijs J, Ederveen AG, de Coster R,
Bouillon R. Aromatase inhibition impairs skeletal modeling and decreases bone
mineral density in growing male rats. Endocrinology. 1997; 138: 2301
-2307.
Vanderschueren D, Van Herck E, Suiker AM, Visser WJ, Schot LP, Bouillon R. Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency. Endocrinology. 1992; 130: 2906 -2916.[Abstract]
Vanderschueren D, Vandenput L, Boonen S, Van Herck E, Swinnen JV,
Bouillon R. An aged rat model of partial androgen deficiency: prevention of
both loss of bone and lean body mass by low-dose androgen replacement.
Endocrinology. 2000; 141: 1642
-1647.
Vermeulen A. Androgen replacement therapy in the aging male—a
critical evaluation. J Clin Endocrinol Metab. 2001; 86: 2380
-2390.
Wakley GK, Schutte HDJ, Hannon KS, Turner RT. Androgen treatment prevents loss of cancellous bone in the orchidectomized rat. J Bone Miner Res. 1991;6: 325 -330.[Medline]
Wiedemann E, Schwartz E, Frantz AG. Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone, and prolactin in man. J Clin Endocrinol Metab. 1976; 42: 942 -952.[Abstract]
Williams GR, Robson H, Shalet SM. Thyroid hormone actions on cartilage and bone: interactions with other hormones at the epiphyseal plate and effects on linear growth. J Endocrinol. 1998; 157: 391 -403.[Medline]
Wronski TJ, Dann LM, Scott KS, Cintron M. Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int. 1989;45: 360 -366.[Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
